Department of Oncology, Affiliated Hospital of Guangdong Medical College, 57 Renmin Road, Zhanjiang, PR China.
Department of Oncology, Zhanjinag Central People's Hospital, 2 Cunjin Road, Zhanjiang, Guangdong, PR China.
Biomed Pharmacother. 2016 Dec;84:123-129. doi: 10.1016/j.biopha.2016.09.027. Epub 2016 Sep 16.
Non-small cell lung cancer (NSCLC) chemoresistance usually limits the clinical efficacy of chemotherapeutic approaches. However, few reports have revealed the regulation of miR-135b and Frizzled-1 (FZD1) involved in NSCLC chemoresistance.
To identify the mechanism of miR-135b and FZD1 in NSCLC chemoresistance and to observe their biological functions, we detected the expression levels of miR-135b and FZD1 by conducting quantitative real-time polymerase chain reaction (RT-qPCR) and modified the expressions of miR-135b and FZD1 by transiently transfecting cells with miR-135b mimics or FZD1-siRNA. The 3'-untranslated region (3'-UTR) of FZD1 combined with miR-135b was verified through dual-luciferase reporter assay.
Compared with that in A549 parental cell lines, the miR-135b expression in drug-resistant lung cancer cell lines (A549/DDP) was decreased and their FZD1 expression was increased. The increased miR-135b expression and silenced FZD1 expression enhanced the sensitivity of resistant cells to cisplatin treatment. The high expression of miR-135b in A549/DDP cells remarkably decreased the mRNA levels of FZD1. FZD1 was further identified as the functional downstream target of miR-135b by directly targeting the 3'-UTR of FZD1.
The amplification of miR-135b suppressed NSCLC chemoresistance by directly mediating the FZD1 downregulation.
非小细胞肺癌(NSCLC)的化疗耐药性通常限制了化疗方法的临床疗效。然而,鲜有报道揭示了 miR-135b 和卷曲蛋白 1(FZD1)在 NSCLC 化疗耐药性中的调节作用。
为了确定 miR-135b 和 FZD1 在 NSCLC 化疗耐药性中的作用机制并观察它们的生物学功能,我们通过定量实时聚合酶链反应(RT-qPCR)检测 miR-135b 和 FZD1 的表达水平,并通过瞬时转染 miR-135b 模拟物或 FZD1-siRNA 来改变 miR-135b 和 FZD1 的表达。通过双荧光素酶报告基因检测验证 FZD1 的 3'-非翻译区(3'-UTR)与 miR-135b 结合。
与亲本细胞系 A549 相比,耐药肺癌细胞系(A549/DDP)中的 miR-135b 表达降低,而 FZD1 表达升高。增加 miR-135b 表达和沉默 FZD1 表达可增强耐药细胞对顺铂治疗的敏感性。A549/DDP 细胞中高表达的 miR-135b 显著降低了 FZD1 的 mRNA 水平。通过直接靶向 FZD1 的 3'-UTR,FZD1 被进一步鉴定为 miR-135b 的功能性下游靶标。
miR-135b 的扩增通过直接介导 FZD1 的下调抑制 NSCLC 化疗耐药性。